Citations (7)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Rui Meng, Xueke Zhang, Ting Zhou, Mengjie Luo & Yijin Qiu. (2022) Cost-effectiveness analysis of donafenib versus lenvatinib for first-line treatment of unresectable or metastatic hepatocellular carcinoma. Expert Review of Pharmacoeconomics & Outcomes Research 22:7, pages 1079-1086.
Read now
Read now
Articles from other publishers (6)
Unchalee Permsuwan, Sumitra Thongprasert & Buntitabhon Sirichanchuen. (2020) Cost-Utility Analysis of First-Line Pemetrexed Plus Cisplatin in Non-Small Cell Lung Cancer in Thailand. Value in Health Regional Issues 21, pages 9-16.
Crossref
Crossref
Iluminada Fuertes-Fuertes, J. David Cabedo & Inmaculada Jimeno-García. (2019) Capturing the Invisible Wealth in Nonprofits to Overcome Myopic Perceptions. Sustainability 12:1, pages 48.
Crossref
Crossref
P. Créquit, J. Cadranel, H. Mal, B. Grigoriu & T. Berghmans. (2019) Transplantation pulmonaire des adénocarcinomes pulmonaires invasifs « lépidiques » : d’une question clinique à une réflexion éthique. Revue des Maladies Respiratoires 36:8, pages 919-923.
Crossref
Crossref
C. Chouaid & A. Vergnenègre. (2018) Les coûts du cancer du poumon. Revue des Maladies Respiratoires Actualités 10:3, pages 192-197.
Crossref
Crossref
Xiaohong Yuan, Pisheng Qu, Jun Fang, Shunv Cai & Shuang Fu. (2018) Effect of Epidural Anesthesia on the Immune Function of Patients with Non-small Cell Lung Cancer. International Journal of Pharmacology 14:6, pages 826-834.
Crossref
Crossref
. (2017) Pemetrexed + cisplatin cost effective for NSCLC in France. PharmacoEconomics & Outcomes News 785:1, pages 28-28.
Crossref
Crossref